Haliodx is a leading brand that specializes in translating the tumor immune response into clear insights to guide treatment decisions, inform biomarker development, and advance therapeutics in the field of oncology diagnostics and research services. With a focus on immunogram, tissue analysis, cancer immune atlas, and biomarker capabilities, Haliodx offers customized biomarker testing and analytical services to its biopharma partners to help them accelerate their therapeutic discovery, development, and commercialization programs. They leverage multiple technologies, proprietary artificial intelligence platforms, and databases to advance precision medicine in the era of immuno-oncology and combination therapies.

Haliodx's unique multi-omic capabilities and expertise optimize biomarkers, companion diagnostics, and therapeutic clinical trials through robust analysis of patient oncology samples. The brand's Immuno-oncology (IO) capabilities, which focus on the immune contexture of tumors, are highly relevant to tumor progression and clinical outcomes. Partnering with Haliodx provides actionable insights and a comprehensive cancer reference database to accelerate the next generation of precision medicine in oncology